A Randomized Controlled Study Evaluating Short-Term Dual Antiplatelet Therapy with Low-Dose Ticagrelor (60 mg) Followed by Monotherapy versus Standard-Duration Dual Antiplatelet Therapy with Clopidogrel in Patients with Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention: the STELAR trial

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-526368-18-00

Enrollment

500

Registered

2026-07-27

Start date

Unknown

Completion date

Unknown

Last updated

2026-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Coronary Syndrome in patients undergoing percutaneous coronary intervention (PCI)

Brief summary

Net adverse clinical events including: cardiovascular death, myocardial infarction, clinically relevant bleeding, stroke, ischemia-driven target vessel revascularization

Detailed description

Ischemic composite including: Cardiovascular Death, Myocardial Infarction (MI), Stroke (ischemic or hemorrhagic), Stent Thrombosis, Ischemia-driven Target Vessel Revascularization (TVR), NACE tested at 12 month, Individual components of the primary endpoint, Any Bleeding (BARC 1–5), Minor Bleeding (BARC 1–2), Unplanned Revascularization (Any Cause), All-cause mortality

Interventions

DRUGAuretica 60 mg compresse rivestite con film

DRUGCARDIOASPIRIN 100 mg Compresse gastroresistenti

DRUGClopidogrel 75 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Net adverse clinical events including: cardiovascular death, myocardial infarction, clinically relevant bleeding, stroke, ischemia-driven target vessel revascularization	—

Secondary

Measure	Time frame
Ischemic composite including: Cardiovascular Death, Myocardial Infarction (MI), Stroke (ischemic or hemorrhagic), Stent Thrombosis, Ischemia-driven Target Vessel Revascularization (TVR), NACE tested at 12 month, Individual components of the primary endpoint, Any Bleeding (BARC 1–5), Minor Bleeding (BARC 1–2), Unplanned Revascularization (Any Cause), All-cause mortality	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 28, 2026